WallStreetZenWallStreetZen

NASDAQ: RNLX
Renalytix PLC Stock

$1.04-0.13 (-11.11%)
Updated Mar 1, 2024
RNLX Price
$1.04
Fair Value Price
-$0.91
Market Cap
$51.96M
52 Week Low
$0.25
52 Week High
$4.04
P/E
-1.16x
P/B
-6.53x
P/S
7.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.41M
Earnings
-$41.85M
Gross Margin
6.3%
Operating Margin
-1,736.18%
Profit Margin
-1,736.5%
Debt to Equity
-2.42
Operating Cash Flow
-$36M
Beta
0.82
Next Earnings
Mar 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RNLX Overview

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RNLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RNLX ($1.04) is overvalued by 214.27% relative to our estimate of its Fair Value price of -$0.91 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RNLX ($1.04) is not significantly undervalued (214.27%) relative to our estimate of its Fair Value price of -$0.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RNLX due diligence checks available for Premium users.

Be the first to know about important RNLX news, forecast changes, insider trades & much more!

RNLX News

Valuation

RNLX fair value

Fair Value of RNLX stock based on Discounted Cash Flow (DCF)
Price
$1.04
Fair Value
-$0.91
Undervalued by
214.27%
RNLX ($1.04) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RNLX ($1.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RNLX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.16x
Industry
88.3x
Market
36.17x

RNLX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-6.53x
Industry
3.69x

RNLX's financial health

Profit margin

Revenue
$709.0k
Net Income
-$8.5M
Profit Margin
-1,196.8%
RNLX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RNLX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$11.3M
Liabilities
$19.2M
Debt to equity
-2.42
RNLX's short-term liabilities ($13.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNLX's short-term assets ($8.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNLX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RNLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.9M
Investing
$0.0
Financing
-$507.0k
RNLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RNLX vs Health Information Service Stocks

TickerMarket Cap1d %P/EP/B
RNLX$51.96M-11.11%-1.16x-6.53x
BEAT$41.60M+8.97%-1.27x2.23x
HLTH$40.98M-17.19%-0.16x0.11x
SNCE$34.27M+0.17%-0.27x0.66x
EUDA$33.95M0.00%N/A-5.70x

Renalytix Stock FAQ

What is Renalytix's quote symbol?

(NASDAQ: RNLX) Renalytix trades on the NASDAQ under the ticker symbol RNLX. Renalytix stock quotes can also be displayed as NASDAQ: RNLX.

If you're new to stock investing, here's how to buy Renalytix stock.

What is the 52 week high and low for Renalytix (NASDAQ: RNLX)?

(NASDAQ: RNLX) Renalytix's 52-week high was $4.04, and its 52-week low was $0.25. It is currently -74.24% from its 52-week high and 324.49% from its 52-week low.

How much is Renalytix stock worth today?

(NASDAQ: RNLX) Renalytix currently has 99,930,156 outstanding shares. With Renalytix stock trading at $1.04 per share, the total value of Renalytix stock (market capitalization) is $51.96M.

Renalytix stock was originally listed at a price of $13.50 in Jul 17, 2020. If you had invested in Renalytix stock at $13.50, your return over the last 3 years would have been -92.3%, for an annualized return of -57.45% (not including any dividends or dividend reinvestments).

How much is Renalytix's stock price per share?

(NASDAQ: RNLX) Renalytix stock price per share is $1.04 today (as of Mar 1, 2024).

What is Renalytix's Market Cap?

(NASDAQ: RNLX) Renalytix's market cap is $51.96M, as of Mar 3, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Renalytix's market cap is calculated by multiplying RNLX's current stock price of $1.04 by RNLX's total outstanding shares of 99,930,156.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.